Gangliosides in vivo reduce diabetes incidence in non-obese diabetic mice.

Non-obese diabetic mice were treated daily with a mixture of gangliosides from day 30 until day 250 of life or until the mice became diabetic. Ganglioside treatment reduced diabetes incidence from 80-90% to 47% and from 20-30% to zero in female and male mice respectively. Gangliosides did not affect the frequency of perivasculitis. It is concluded that gangliosides can reduce diabetes incidence in non-obese diabetic mice.